- H.C. Wainwright analyst Ananda Ghosh reaffirmed a buy rating on IVA stock with a price target of 14 dollars.
- The evaluation is driven by an estimated 85 percent probability of success for the NATiV3 trial of lanifibranor in treating MASH.
- Despite existing risks, the company's valuation of approximately 840,000,000 dollars presents an asymmetric risk-return profile.